Our story

We are committed to building a future together by staying true to our heritage over the past 110 years of adapting, innovating and growing.

Founder Victor Stein extracts sodium alginate from seaweed imported from the North Sea, which he names Norgine.

Norgine launches pharma products and a few years later becomes a supplier of insulin in Europe.

Norgine is re-established in Western Europe.

Manufacturing starts in our current Dreux and Hengoed sites.

Norgine licenses in and launches KLEAN-PREP®.

Norgine develops and launches MOVICOL® and MOVIPREP®. MOVIPREP® becomes Norgine’s first product approved in the USA.

Norgine enters joint venture with SpePharm to acquire their products.

Norgine launches XIFAXAN® for patients with hepatic encephalopathy.

Norgine acquires Merus Labs International Inc. EU approves PLENVU®, the world’s first one litre PEG bowel preparation.

Norgine in-licenses FERACCRU®. FDA approves PLENVU®.

Launch of MOVIPREP® in
Japan – our first 
product in Japan.

AMAG Pharmaceuticals and Norgine B.V. enter into exclusive licensing agreement in Europe, Australia and New Zealand to commercialize Ciraparantag.

Norgine B.V. and
US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (Eflornithine) in Europe, Commonwealth of Independent States, Australia & New Zealand.

Goldman Sachs Asset Management acquires a $2 billion majority stake in the Company.